Today: 14 June 2026
Browse Category

NASDAQ:SHPH 21 November 2025 - 4 June 2026

Shuttle Pharmaceuticals (SHPH) Stock Soars on S‑1 Filing, Fresh Financing and AI Pivot – What Today’s Volatile Rally Means for Investors (21 Nov 2025)

Shuttle Pharmaceuticals (SHPH) Stock Soars on S‑1 Filing, Fresh Financing and AI Pivot – What Today’s Volatile Rally Means for Investors (21 Nov 2025)

Shuttle Pharmaceuticals (NASDAQ: SHPH) jumped over 25% in after-hours and pre-market trading on November 21, 2025, after filing a new S-1 registration statement. The filing registers 625,156 shares tied to a pre-funded warrant held by Alternative Investment Capital Inc., which could control about 47% of shares post-offering. Shuttle will not receive new proceeds, as cash was raised in a prior $2.5 million private placement.
21 November 2025
···

Stock Market Today

  • Top 2 Cryptocurrencies to Buy Now: Bitcoin and Hyperliquid
    June 13, 2026, 9:15 PM EDT. In the current crypto bear market, only two cryptocurrencies stand out for investment: Bitcoin (BTC) and Hyperliquid (HYPE). Bitcoin remains strong due to its capped supply of 21 million coins, with a supply cut expected in 2028 through a process called halving, which historically supports price rises. Despite volatility, long-term prospects depend on supply constraints. Hyperliquid, a decentralized trading platform, offers investors real cash flow via a token buyback and burn mechanism fueled by trading fees, effectively reducing supply and increasing value. Since January 2025, over $2 billion worth of tokens have been burned, highlighting its potential as a yield-generating asset. These fundamental strengths drive continued accumulation by investors amid market uncertainty.

Latest articles

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

14 June 2026
Kraft Heinz closed up 0.70% at $24.39, outpacing the S&P 500, as investors weighed its 6.6% dividend yield against falling organic sales, lower adjusted earnings, and cautious analyst targets; the next earnings update is seen as the key test for whether $600 million in marketing and R&D can revive growth and support the stock’s rebound.
Go toTop